Lamy R, Conroy T, Brunaud L, Bresler L
Département d'Oncologie Médicale, Centre Alexis-Vautrin, France.
Gastroenterol Clin Biol. 2001 Oct;25(10):912-3.
Pancreatic adenocarcinoma tissue contains estrogen receptors and some pilot studies have suggested that tamoxifen could increase the survival of patients with unresectable pancreatic cancer. However data of comparative studies are conflicting. We report the case of a woman who presented with unresectable pancreatic head carcinoma with hepatic metastasis. The patient refused chemotherapy and was treated with tamoxifen 30 mg/day. A complete clinical remission of 50 months was observed. A further large-scale study may be required to assess the usefulness of tamoxifen in the second-line treatment of advanced pancreatic carcinoma.
胰腺腺癌组织含有雌激素受体，一些初步研究表明他莫昔芬可提高不可切除胰腺癌患者的生存率。然而，比较研究的数据相互矛盾。我们报告了一例患有不可切除的胰头癌并伴有肝转移的女性病例。该患者拒绝化疗，接受了每天30毫克他莫昔芬的治疗。观察到完全临床缓解达50个月。可能需要进一步的大规模研究来评估他莫昔芬在晚期胰腺癌二线治疗中的有效性。
